


Riluzole-¹³C,¹⁵N₂

Cat. No.:	HY-B0211S
CAS No.:	1215552-03-6
Molecular Formula:	C ₇ ¹³ CH ₅ F ₃ ¹⁵ N ₂ OS
Molecular Weight:	237.18
Target:	GABA Receptor; Sodium Channel
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Riluzole- ¹³ C, ¹⁵ N ₂ is the ¹³ C and ¹⁵ N labeled Riluzole[1]. Riluzole is an anticonvulsant agent and belongs to the family of use-dependent Na ⁺ channel blocker which can also inhibit GABA uptake with an IC ₅₀ of 43 μM[2][3].
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019 Feb;53(2):211-216.
- [2]. He Y, et al. Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function. *Neuropharmacology*. 2002 Feb;42(2):199-209.
- [3]. Thompson JM, et al. Small-conductance calcium-activated potassium (SK) channels in the amygdala mediate pain-inhibiting effects of clinically available riluzole in a rat model of arthritis pain. *Mol Pain*. 2015 Aug 28;11:51.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA